The aim of this study was therefore to assess whether the I148M PNPLA3 variant influences adiponectin in patients with liver diseases characterized by altered adiponectin activity and whose disease progression is influenced by this genetic variant and steatosis, i.e. NASH and CHC, and in healthy controls with a very low probability of steatosis. This evidence concerns the gene ADIPOQ and steatosis.